secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-021133
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector reports Q4 net loss $41.4M; cash runway extended to 2026 after $75M equity offering
--------------------------------------------------------------------------------

- Q4 net loss $41.4M ($0.49/sh) vs $52.4M ($0.63) YoY; FY net loss $130.4M ($1.56) vs $133.3M ($1.62).
- Cash $548.9M at Dec 31; pro forma $620M after Jan 2024 equity offering, providing runway through 2026.
- INVOKE-2 Phase 2 enrollment completed (381 pts); data due Q4 2024. Latozinemab granted FDA Breakthrough Therapy for FTD-GRN.
- First patient dosed in PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early AD in Feb 2024.
- 2024 guidance: collaboration revenue $60-70M, R&D $210-230M, G&A $60-70M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017024021133/0000950170-24-021133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017024021133/alec-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-021133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer